Semaglutide vs Retatrutide
Written by Aaron CuhaReviewed Sep 2026
The short answer
One switch against three. Retatrutide's large final stage trial, TRIUMPH-1, reported in May 2026 and a filing is expected late in the year. So this pairs a drug with years of use after approval against one whose record looks complete on paper and is untested in everyday use.
- Semaglutide people
- 42,363
- Semaglutide nulls
- 2
- Retatrutide people
- 1,345
- Retatrutide nulls
- 0
Dose
Approved titration: 0.25, 0.5, 1, 1.7 and 2.4 mg
0.25, 0.5, 1, 1.7 and 2.4 mg
The approved semaglutide ladder, in mg.
Dose
Trial titration, not approved: 1, 2, 4, 8 and 12 mg
1, 2, 4, 8 and 12 mg
Doses used across the retatrutide trials, in mg. Not an approved ladder.
First-hand reports are counted on each profile and never added together. This page sets two published records side by side. It does not pick a winner.
Column A
SemaglutideSemaglutide (GLP-1 receptor agonist)
A once a week shot for type 2 diabetes and weight loss. It is approved, and big studies show it also lowers the risk of heart attack and stroke.
Column B
RetatrutideRetatrutide (triple GLP-1/GIP/glucagon agonist)
A weekly shot that is still being tested. It works on three hunger and blood sugar signals. It has led to the most weight loss of any drug in studies so far.
Side by side, on the facts we can check
| What we compare | Semaglutide | Retatrutide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | FDA-approved (Ozempic and Rybelsus for type 2 diabetes; the Wegovy shot, the Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management) | Investigational, not FDA-approved. Results from TRIUMPH-1, a final-stage study, came out in May 2026. The maker expects to ask the FDA for approval in late 2026 |
| Half-life | ~7 days | ~6 days |
| Molecular weight | 4,113.6 Da | ~4,731 Da |
| How it works | It switches on the GLP-1 receptor, a switch on cells that normally answers a gut hormone after you eat. That makes the body release insulin when blood sugar is high. It holds back glucagon, a hormone that raises blood sugar. It slows how fast the stomach empties. It also acts on the part of the brain that runs hunger, so people eat less. | It switches on three receptors: GLP-1, GIP and glucagon. The glucagon part makes the body burn more energy and burn more fat in the liver. The other two turn down hunger and help the body release insulin. |
| Studies in people | 15 | 11 |
| Evidence | Strong: 12 completed trials, 42,363 people given it | Strong: 5 completed trials, 1,345 people given it |
| Legal status, US | FDA-approved, prescription only | Investigational, not approved for any use |
Frequently asked questions
What is the difference between Semaglutide and Retatrutide?
Semaglutide: A once a week shot for type 2 diabetes and weight loss. It is approved, and big studies show it also lowers the risk of heart attack and stroke. Retatrutide: A weekly shot that is still being tested. It works on three hunger and blood sugar signals. It has led to the most weight loss of any drug in studies so far.
Which has stronger research evidence, Semaglutide or Retatrutide?
Each compound gets a band worked out from facts we counted, with the math shown. Semaglutide is Strong (12 completed trials, 42,363 people given it). Retatrutide is Strong (5 completed trials, 1,345 people given it). That counts how much has been done in people. It does not rate whether either one works, and neither one is called the winner.
Are Semaglutide and Retatrutide FDA-approved?
Semaglutide: FDA-approved (Ozempic and Rybelsus for type 2 diabetes; the Wegovy shot, the Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management). Retatrutide: Investigational, not FDA-approved. Results from TRIUMPH-1, a final-stage study, came out in May 2026. The maker expects to ask the FDA for approval in late 2026.
Related posts
Blog articles that cover Semaglutide or Retatrutide, newest first.
- Dispatch / Sep 27, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 27, 2026 / 8 minTesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
- Longevity / Sep 27, 2026 / 12 minPeptides for Longevity: What the Evidence Actually Shows in 2026
- Metabolic / Sep 27, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
Reviewed Sep 2026. This page puts two published records side by side. It is for learning, and it is not medical advice. When this site shows a dose, it is the dose a trial or a clinic actually used, or what people say they did, with the source attached. None of it tells you what to take.